70
Participants
Start Date
February 28, 2002
Primary Completion Date
March 31, 2003
Study Completion Date
March 31, 2003
belimumab
"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
belimumab
"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
belimumab
"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
belimumab
"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
Placebo
"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
Hospital for Joint Diseases, New York
North Shore University Hospital, Manhasset
SUNY Downstate Medical Center, Brooklyn
University of Pittsburgh School of Medicine, Pittsburgh
Washington Hospital Center, Washington D.C.
Wake Forest University School of Medicine, Winston-Salem
The University of North Carolina at Chapel Hill, Chapel Hill
Duke University, Durham
Medical University of South Carolina, Charleston
University of Alabama at Birmingham, Birmingham
The University of Michigan Health System, Ann Arbor
Northwestern University Medical School, Chicago
Rush-Presbyterian-St Luke's Medical Center, Chicago
The University of Chicago Hospital, Chicago
Oklahoma Medical Research Foundation, Oklahoma City
University of Texas Southwestern Medical Center at Dallas, Dallas
University of Southern California, Los Angeles
University of California-Los Angeles, Los Angeles
Lead Sponsor
Human Genome Sciences Inc.
INDUSTRY